Potency of HDM Sublingual AIT Tablets in Assuring the Persistency of Asthma Control in HDM Allergic Patients With Severe Asthma, Treated With Tezepelumab

NCT07013123 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Severe Asthma
Allergy to House Dust Mites

Interventions

DRUG: Tezepelumab
DRUG: Acarizax
DRUG: Placebo

Sponsor

University Hospital, Montpellier

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]